By Fineline Cube 
US-based pharmaceutical giant Merck, Sharp & Dohme (MSD, NYSE: MRK) has announced the establishment of a state-of-the-art Biologics Center of Excellence in Wilmington, Delaware. The USD 1 billion project spans 470,000 square feet and underscores Merck’s commitment to advancing American innovation and infrastructure.
Facility Overview
The facility will integrate laboratory, manufacturing, and warehouse operations to support the development and commercial production of next-generation biologics and therapies. This includes potent antibody-drug conjugates (ADCs), reinforcing the company’s strategy to diversify its drug pipeline.
Keytruda Production
Notably, the site will also produce Keytruda (pembrolizumab), positioning it as the future hub for U.S. supply of this leading oncology drug. This investment aims not only to enhance domestic access to Keytruda for American patients but also to consolidate MSD’s biologics portfolio in the U.S. market.
Future Plans
MSD has outlined plans for additional expansions at the Wilmington site to accommodate its growing biologics pipeline.-Fineline Info & Tech